<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04655599</url>
  </required_header>
  <id_info>
    <org_study_id>APD371-106</org_study_id>
    <nct_id>NCT04655599</nct_id>
  </id_info>
  <brief_title>Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome</brief_title>
  <official_title>Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arena Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arena Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1b study to determine the effect of oral olorinab on gastrointestinal transit in&#xD;
      adult participants with irritable bowel syndrome (IBS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, randomized, crossover, double-blind, placebo-controlled study&#xD;
      designed to evaluate the effects of olorinab on gastric, small-bowel, and colonic transit in&#xD;
      IBS participants with predominant constipation (IBS-C) or with predominant diarrhea (IBS-D).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Strategic business decision&#xD;
  </why_stopped>
  <start_date type="Actual">January 29, 2021</start_date>
  <completion_date type="Actual">April 13, 2021</completion_date>
  <primary_completion_date type="Actual">April 13, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Colonic transit geometric center after consumption of radiolabeled meal, based on the delivery of activated charcoal in a methacrylate-coated capsule</measure>
    <time_frame>up to 24 hours 30 minutes after consumption of radiolabeled meal</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Gastric emptying half-life (t½) as determined by scintigraphic imaging of radiolabeled meal</measure>
    <time_frame>up to 4 hours 10 minutes after consumption of radiolabeled meal</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Colonic transit geometric center after consumption of radiolabeled meal, based on the delivery of activated charcoal in a methacrylate-coated capsule</measure>
    <time_frame>up to 48 hours 30 minutes after consumption of radiolabeled meal</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ascending colon emptying t½ of radiolabeled activated charcoal particles delivered in a methacrylate-coated capsule</measure>
    <time_frame>up to 24 hours 30 minutes after consumption of radiolabeled meal</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric emptying after radiolabeled meal</measure>
    <time_frame>at 2 hours ± 10 minutes and 4 hours ± 10 minutes after consumption of radiolabeled meal</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and severity of adverse events</measure>
    <time_frame>Up to approximately 6 weeks</time_frame>
    <description>Safety will be assessed by monitoring adverse events and clinically relevant changes in vital signs and clinical laboratory results.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Olorinab, Then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will first receive olorinab, followed by a washout period, and they then will receive placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Then Olorinab</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will first receive placebo, followed by a washout period, and they then will receive olorinab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olorinab</intervention_name>
    <description>Olorinab tablet by mouth, 3 times a day for 4 days with a final dose on Day 5.</description>
    <arm_group_label>Olorinab, Then Placebo</arm_group_label>
    <arm_group_label>Placebo, Then Olorinab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Olorinab matching placebo tablet by mouth, 3 times a day for 4 days with a final dose on Day 5.</description>
    <arm_group_label>Olorinab, Then Placebo</arm_group_label>
    <arm_group_label>Placebo, Then Olorinab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of irritable bowel syndrome (IBS) with predominant constipation (IBS-C) or&#xD;
             IBS with predominant diarrhea (IBS-D) according to Rome IV criteria at Screening&#xD;
&#xD;
          -  Body mass index (BMI) 18.0 to 40.0 kilograms per square meter (kg/m^2), inclusive at&#xD;
             Screening&#xD;
&#xD;
          -  Negative test results for alcohol and selected drugs at Screening and Day 1&#xD;
&#xD;
          -  Negative hepatitis panel (including hepatitis B surface antigen [HBsAg] and hepatitis&#xD;
             C virus antibody [anti-HCV]) and negative for human immunodeficiency virus (HIV)&#xD;
             antibody screens at Screening&#xD;
&#xD;
          -  Participants with recent (within 6 months of Screening) or ongoing alarm features&#xD;
             (unexplained weight loss, nocturnal symptoms, blood mixed with stool) are to have had&#xD;
             a diagnostic colonoscopy prior to Screening and after the onset of alarm features (for&#xD;
             participants with alarm features) to exclude non-IBS conditions per the Rome IV&#xD;
             diagnostic algorithm for IBS&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Structural or metabolic diseases/conditions that affect the gastrointestinal system&#xD;
&#xD;
          -  Diagnosis of IBS with mixed bowel habits (IBS-M) or unsubtyped IBS (IBS-U)&#xD;
&#xD;
          -  Unable to withdraw medications that alter gastrointestinal (GI) transit for 72 hours&#xD;
             prior to baseline colonic transit assay through the duration of treatment period, with&#xD;
             the exception of rescue medicine usage (bisacodyl and loperamide)&#xD;
&#xD;
          -  Clinically relevant changes in dietary, lifestyle, or exercise regimen within 30 days&#xD;
             prior to Screening and for the duration of the study that may confound efficacy&#xD;
             assessments in the clinical judgment of the Investigator (or designee)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arena CT.gov Administrator</last_name>
    <role>Study Director</role>
    <affiliation>Arena Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 19, 2020</study_first_submitted>
  <study_first_submitted_qc>December 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2020</study_first_posted>
  <last_update_submitted>May 13, 2021</last_update_submitted>
  <last_update_submitted_qc>May 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Olorinab</keyword>
  <keyword>APD371</keyword>
  <keyword>Irritable bowel syndrome</keyword>
  <keyword>IBS</keyword>
  <keyword>IBS with predominant constipation</keyword>
  <keyword>IBS-C</keyword>
  <keyword>IBS with predominant diarrhea</keyword>
  <keyword>IBS-D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

